Chishala Chabala
Overview
Explore the profile of Chishala Chabala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
413
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsirizani L, Mohsenian Naghani S, Waalewijn H, Szubert A, Mulenga V, Chabala C, et al.
J Antimicrob Chemother
. 2024 Sep;
79(11):2990-2998.
PMID: 39302766
Background: Darunavir is a potent HIV protease inhibitor with a high barrier to resistance. We conducted a nested pharmacokinetic sub-study within CHAPAS-4 to evaluate darunavir exposure in African children with...
2.
Jacobs T, Waalewijn H, Houlden L, Bollen P, Nanduudu A, Nambi E, et al.
Br J Clin Pharmacol
. 2024 Sep;
90(11):2947-2952.
PMID: 39228168
Dolutegravir (DTG) is primarily metabolized by uridine diphosphate glucuronosyltransferases, forming the pharmacologically inactive DTG glucuronide (DTG-gluc). We described the dolutegravir metabolic ratio (DTG-MR; DTG-gluc AUC divided by DTG AUC) in...
3.
Chabala C, Roucher C, Ton Nu Nguyet M, Babirekere E, Inambao M, Businge G, et al.
EClinicalMedicine
. 2024 Jul;
73:102688.
PMID: 39007063
Background: In children with severe acute malnutrition (SAM) tuberculosis is common, challenging to diagnose, and often fatal. We developed tuberculosis treatment decision algorithms (TDAs) for children under the age of...
4.
Chabala C, Wobudeya E, van der Zalm M, Kapasa M, Raichur P, Mboizi R, et al.
Clin Infect Dis
. 2024 Apr;
79(1):70-77.
PMID: 38592950
Background: Children with human immunodeficiency virus (HIV, CWH) are at high risk of tuberculosis (TB) and face poor outcomes, despite antiretroviral therapy (ART). We evaluated outcomes in CWH and children...
5.
Hasan N, Nourse C, Schaaf H, Bekker A, Loveday M, Alcantara Gabardo B, et al.
Lancet Child Adolesc Health
. 2024 Mar;
8(5):369-378.
PMID: 38522446
Infants born to mothers with tuberculosis disease are at increased risk of developing tuberculosis disease themselves. We reviewed published studies and guidelines on the management of these infants to inform...
6.
Galileya L, Wasmann R, Chabala C, Rabie H, Lee J, Njahira Mukui I, et al.
PLoS Med
. 2023 Nov;
20(11):e1004303.
PMID: 37988391
Background: The current World Health Organization (WHO) pediatric tuberculosis dosing guidelines lead to suboptimal drug exposures. Identifying factors altering the exposure of these drugs in children is essential for dose...
7.
Jacobs T, Mumbiro V, Cassia U, Zimba K, Nalwanga D, Ballesteros A, et al.
Clin Infect Dis
. 2023 Oct;
78(3):702-710.
PMID: 37882611
Background: We evaluated dolutegravir pharmacokinetics in infants with human immunodeficiency virus (HIV) receiving dolutegravir twice daily (BID) with rifampicin-based tuberculosis (TB) treatment compared with once daily (OD) without rifampicin. Methods:...
8.
Chabala C, Jacobs T, Moraleda C, Ndaferankhande J, Mumbiro V, Passanduca A, et al.
J Pediatric Infect Dis Soc
. 2023 Oct;
12(11):581-585.
PMID: 37843384
Optimal antituberculosis therapy is essential for favorable clinical outcomes. Peak plasma concentrations of first-line antituberculosis drugs in infants with living HIV receiving WHO-recommended dosing were low compared with reference values...
9.
Chabala C, Turkova A, Kapasa M, LeBeau K, Tembo C, Zimba K, et al.
Pediatr Infect Dis J
. 2023 Jul;
42(10):899-904.
PMID: 37506295
Background: Lopinavir/ritonavir plasma concentrations are profoundly reduced when co-administered with rifampicin. Super-boosting of lopinavir/ritonavir is limited by nonavailability of single-entity ritonavir, while double-dosing of co-formulated lopinavir/ritonavir given twice-daily produces suboptimal...
10.
Waalewijn H, Szubert A, Wasmann R, Wiesner L, Chabala C, Bwakura-Dangarembizi M, et al.
Clin Infect Dis
. 2023 Jun;
77(6):875-882.
PMID: 37315296
Background: We evaluated the pharmacokinetics of tenofovir alafenamide fumarate (TAF) and tenofovir in a subset of African children enrolled in the CHAPAS-4 trial. Methods: Children aged 3-15 years with human...